Compare AbCellera Biologics Inc (ABCL) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Enphase Energy Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Enphase Energy Inc trades at $41.41 (market cap $5.67B). The key difference: Enphase Energy Inc is far larger — about 2.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | ENPH | |
|---|---|---|
Market Cap | $2.35B | $5.67B |
Sector | Health | Technology |
52-Week High | $8.12 | $72.33 |
52-Week Low | $2.78 | $26.12 |
Enterprise Value | $1.99B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ENPH trades at $42.99, down 0.19% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 EPS of $0.47, beating expectations, but revenue declined to $1.47B in 2025 from $2.3B in 2023. Recent news highlights its entry into AI data center power standards and new product launches, including IQ9N microinverters.
Outlook is mixed: analyst consensus is a 'Hold' with a $41.61 price target, below the current price. Opportunities include expansion into AI-driven energy solutions, but risks involve revenue volatility, high valuation multiples, and competitive pressures in the solar sector. Net cash flow remains positive but has weakened from prior years.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
